Abstract Library

#3479 Mesenteric fibrosis in SI-NEN is characterized by strong dysregulation of CXCL9, IL6, COMP and COL6A6 genes

Introduction: Small intestine neuroendocrine neoplasms (SI-NENs) are characterized by the development of desmoplastic mesenteric fibrosis (MF) in up to 50 % of cases. This can cause intestinal obstruction and ischemia, which is a significant clinical problem.

Conference:

Presenting Author:

Authors: Graf S, Keber C, Hattesohl A, Denkert C, Di Fazio P,

Keywords: si-nen, si-net, comp, col6a6, cxcl9, il6, mesenteric fibrosis, desmoplasia, desmoplastic reaction, tumor microenvironment, tme, tumor stroma interaction, next generation sequencing, ngs, htg edgeseq, gene expression analysis, rna,

#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery

Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, Elio G,

Keywords: Functioning pancreatic neuroendocrine tumors, pancreatic surgery,

#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Landoni L, Nessi C, Muffatti F,

Keywords: pancreatic neuroendocrine tumors, recurrence, surgery, locoregional treatment, systemic treatment,

#2243 Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series.

Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Nessi C, Paiella S, Miotto M, Viviani E, Zingaretti C,

Keywords: somatostatin analogs, resectable pnets,

#2241 Patterns of Recurrence after Resection for Pancreatic Neuroendocrine Tumors: Who, When, and How?

Introduction: Pancreatic Neuroendocrine Tumors (pNETs) represent an increasing indication for pancreatic resection, but there are only few data about their possible recurrence after surgery.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Masini G, Andrianello S, Marchegiani G, Nessi C, Capelli P,

Keywords: neuroendocrine, pancreas, surgery, recurrence, follow-up,